Synapse - Works

Results (13087)

Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Meeting Abstract

Nowakowski, G. S.; Yoon, D. H.; Joffe, E.; Zinzani, P. L.; Sabatelli, L.; Waltl, E. E.; Alvero, C. G.; Hess, G.; Riedell, P. A.; Kim, K.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Long-term outcomes of adrenal insufficiency (AI) due to anti-PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer

Meeting Abstract

Nguyen, B.; Shah, N. J.; Knezevic, A.; Newman, S.; Fitzgerald, K. N.; Kotecha, R.; Lee, C. H.; Carlo, M. I.; Aggen, D. H.; Feldman, D. R.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma

Meeting Abstract

Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition

Meeting Abstract

Nacev, B. A.; Bradic, M.; Richards, A. L.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Chi, P.; Movva, S.; Thornton, K. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results

Meeting Abstract

Mims, A. S.; Huang, Y.; Eisenmann, E.; Buelow, D.; Swords, R. T.; Foster, M. C.; Lin, T. L.; Baer, M. R.; Kovacsovics, T.; Al-Mansour, Z.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)

Meeting Abstract

Middleton, M. R.; Hamid, O.; Shoushtari, A. N.; Meier, F. E.; Bauer, T. M.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P.; Mauch, C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Alliance A059102: A randomized phase II US intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas

Meeting Abstract

Mehta-Shah, N.; Geyer, S. M.; Barta, S. K.; Amengual, J. E.; Dockter, T.; Wright, C.; Dinner, S.; Hsi, E. D.; Bartlett, N. L.; Horwitz, S. M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma

Meeting Abstract

McKean, M.; Aggen, D. H.; Lakhani, N. J.; Bashir, B.; Luke, J. J.; Hoffman-Censits, J. H.; Alhalabi, O.; Bowman, I. A.; Guancial, E. A.; Tan, A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Meeting Abstract

Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Izquierdo, A. R.; Martin, E. M. D.; Garcia-Sancho, A. M.; Sandoval-Sus, J. D.; Tilly, H.; Vandenberghe, E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies

Meeting Abstract

Mato, A.; Danilov, A. V.; Patel, M. R.; Tees, M. T.; Flinn, I. W.; Ai, W. Z.; Patel, K.; Wang, M.; O'Brien, S. M.; Nandakumar, S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save